Ratings Modern Dental Group Limited

Equities

3600

KYG618201092

Delayed Hong Kong S.E. Other stock markets 03:24:40 2024-04-29 am EDT			5-day change	1st Jan Change
4.79 ^HKD	-1.64%		+1.91%	+11.40%

Mar. 26	Modern Dental Group Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 28 June 2024	CI
Mar. 26	Modern Dental Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Strengths

The company returns high margins, thereby supporting business profitability.
The company's attractive earnings multiples are brought to light by a P/E ratio at 9.96 for the current year.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
MODERN DENTAL GROUP LIMITED	+11.40%	589M		-
STRAUMANN HOLDING AG	+2.43%	24.07B		B
SONOVA HOLDING AG	-6.09%	16.75B		A
COCHLEAR LIMITED	+8.42%	13.7B		B
DEMANT A/S	+12.23%	10.18B		B-
EYEBRIGHT MEDICAL TECHNOLOGY (BEIJING) CO., LTD.	-17.75%	2.06B		-
EMBLA MEDICAL HF.	+6.38%	1.79B		B+
ANGEL ROBOTICS CO., LTD.	0.00%	400M	-	-
DELCATH SYSTEMS, INC.	+27.40%	135M		-
INTEGRUM AB	+20.92%	93.49M		-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes